Haemonetics
169 hedge funds and large institutions have $2.41B invested in Haemonetics in 2015 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 77 increasing their positions, 54 reducing their positions, and 17 closing their positions.
121% more call options, than puts
Call options by funds: $526K | Put options by funds: $238K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 54
19% more capital invested
Capital invested by funds: $2.03B → $2.41B (+$386M)
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
1.14% less ownership
Funds ownership: 105.54% → 104.4% (-1.1%)
2% less funds holding
Funds holding: 172 → 169 (-3)
Top Buyers
Top Sellers
HAE Hedge Fund Activity: Q1 2015 in Review
169 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2015, worth a combined $2.41B — up 19% from $2.03B a quarter earlier.
Fund positioning in HAE was balanced in Q1 2015: 17 funds opened new positions, 17 closed out, 77 added to existing stakes and 54 trimmed.
The largest buyer was Westwood Holdings Group, adding an estimated $16M. The largest seller was Vaughan Nelson Investment Management, cutting an estimated $40.4M.
- 169 institutional investors held Haemonetics (HAE) as of Q1 2015, down from 172 in Q4 2014.
- Funds reported $2.41B of Haemonetics stock for Q1 2015, up 19% quarter-over-quarter.
- 17 funds opened new Haemonetics positions in Q1 2015 and 17 closed out, a net change of 0 holders.
- The largest Haemonetics buyer in Q1 2015 was Westwood Holdings Group, an estimated $16M added.
- The largest Haemonetics seller in Q1 2015 was Vaughan Nelson Investment Management, an estimated $40.4M sold.
Based on aggregated 13F filings for Q1 2015.